AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02021539 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical ultrasound +elastography 1
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
Study NCT02021539 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaginal fibronectin measurement
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
Study NCT02021539 — intervention group
Intervention type: DRUG
Intervention: Tocolytic treatment for 2 hours
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
Study NCT02021539 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical ultrasound +elastography 2
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
Study NCT00095823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant + Placebo
Description: Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study NCT00095823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant + Aripiprazole
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Study NCT00617721 — intervention group
Intervention type: OTHER
Intervention: Blood withdrawal
Description: Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
Study NCT03842553 — intervention group
Intervention type: OTHER
Intervention: No Intervention: anonymous online survey
Study NCT01137123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three field Lymphadenectomy
Description: Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
Study NCT00829608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Vaccine
Description: 0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
Study NCT00518713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam Low Dose
Description: 0.25 mg/kg/day; tablets; orally; for 15-18 weeks
Study NCT00518713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam Medium Dose
Description: 0.5 mg/kg/day; tablets; orally; for 15-18 weeks
Study NCT00518713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam High Dose
Description: 1.0 mg/kg/day; tablets; orally; for 15-18 weeks
Study NCT00518713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets; orally; daily for 15-18 weeks
Study NCT01051063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A
Description: Intramuscular injection
Study NCT00836654 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Catumaxomab (Removab)
Description: Puncture free survival
Study NCT00836654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paracentesis
Study NCT00519636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FPNS
Description: fluticasone propionate nasal spray
Study NCT00519636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FFNS
Description: fluticasone furoate nasal spray
Study NCT00519636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FFNS
Description: placebo nasal spray matching fluticasone furoate nasal spray
Study NCT00519636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FPNS
Description: placebo nasal spray matching fluticasone propionate nasal spray
Study NCT03762629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
Study NCT03240939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride 0.5 mg
Description: single dose
Study NCT03240939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5 mg
Description: single dose
Study NCT03240939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-201
Description: single dose
Study NCT03464604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: active
Description: Pre-screening for melanoma by qualified nurse
Study NCT03241524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program for pelvic muscle floor
Description: Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
Study NCT03109340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised treadmill group (Group I)
Description: An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
Study NCT03109340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECE PEDO pedometer (Group II)
Description: Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
Study NCT02023879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
Study NCT02023879 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alirocumab
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
Study NCT02023879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alirocumab
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
Study NCT02023879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Alirocumab)
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
Study NCT02023879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Alirocumab)
Description: Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
Study NCT02023879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-statin LMT
Description: Ezetimibe or Fenofibrate at stable dose as background therapy.
Study NCT02023879 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Non-statin LMT
Description: Ezetimibe or Fenofibrate at stable dose as background therapy.
Study NCT02023879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-statin LMT
Description: Ezetimibe or Fenofibrate at stable dose as background therapy.
Study NCT02023879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.
Study NCT02023879 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.
Study NCT02023879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet Alone
Description: Stable cholesterol-lowering diet as background therapy.
Study NCT01243073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Study NCT01671748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIST ultrasound therapy
Description: Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
Study NCT01671748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Compression bandaging, non-adherent dressing, and debridement if required.
Study NCT01671748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Compression bandaging, non-adherent dressing, and debridement if required.
Study NCT02344394 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic Cryoballoon
Description: For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
Study NCT04469452 — intervention group
Intervention type: DEVICE
Intervention: Apollo Device
Description: Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
Study NCT01915992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Study NCT01915992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Study NCT02990364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
Study NCT02990364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
Study NCT02990364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA Topical Product
Description: EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
Study NCT03180008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fit and Strong!
Description: Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
Study NCT03180008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong! Plus
Description: The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
Study NCT04093466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1003
Description: Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
Study NCT04473118 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: An online-based questionnaire sent to participants via email
Study NCT03792789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mCIMT with real rTMS
Description: Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses).
Study NCT03792789 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: mCIMT with sham rTMS
Description: Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil.
Study NCT00985530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Self-administered tablets BID (approximately one hour after breakfast \& dinner) during each 6 week cycle
Study NCT00985530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
Study NCT02453802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp
Description: Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
Study NCT02453802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 5%,5ml/amp
Description: IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
Study NCT02453802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
Study NCT02453802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban (10mg)
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
Study NCT02453802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
Study NCT02453802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
Study NCT02453802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Topical 160 ml normal saline application after closure of joint capsule.
Study NCT02453802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Topical 160 ml normal saline application after closure of joint capsule.
Study NCT04463056 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Soliris®
Description: Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
Study NCT00438243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac (Xibrom)
Description: 1 drop to affected eye twice daily.
Study NCT00438243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Plus
Description: 1 drop in the affected eye twice daily
Study NCT02968433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusions of young plasma
Description: Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
Study NCT02231879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor
Description: Twice daily low dose injection for 14 months.
Study NCT02231879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Twice daily low dose injection for 14 months.
Study NCT02091297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
Study NCT02091297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
Study NCT02091297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia
Study NCT04393220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: 15mg/kg (Q3W)
Study NCT04393220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: 15mg/kg (Q3W)
Study NCT04393220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 480 mg IV infusions for 30 minutes q4w
Study NCT04393220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: nivolumab 480 mg IV infusions for 30 minutes q4w
Study NCT05525442 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous cholecystostomy
Description: Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.
Study NCT01171781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin (3 weekly)
Description: radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
Study NCT01171781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin (weekly)
Description: radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
Study NCT01088880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT01073228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVP-6124
Study NCT01073228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02091297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02730377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study NCT02730377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha-glucosidase inhibitors
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study NCT02730377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 inhibitors
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
Study NCT02730377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: meglitinides
Description: Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.